Abstract
Despite significant improvements in treatment strategies over the past couple of decades, multiple myeloma (MM) remains an incurable disease due to the development of drug resistance. Metabolic reprogramming is a key feature of cancer cells, including MM, and acts to fuel increased proliferation, create a permissive tumour microenvironment, and promote drug resistance. This review presents an overview of the key metabolic adaptations that occur in MM pathogenesis and in the development of resistance to proteasome inhibitors, the backbone of current MM therapy, and considers the potential for therapeutic targeting of key metabolic pathways to improve outcomes.
| Original language | English |
|---|---|
| Article number | 1682 |
| Journal | Cancers |
| Volume | 15 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 09 Mar 2023 |
Access to Document
- Metabolic alterations in multiple myeloma: from oncogenesis to proteasome inhibitor resistance
Copyright 2023 the authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.